PrecisemAb Successfully Develops Universal Antibody Lock to Overcome the Trade Off Between Efficacy and Toxicity in Cancer Therapy
We sincerely thank ESGtimes – Sustainable Times for the interview and in-depth feature, which allows more…
Latest News
Read MorePrecisemAb Successfully Develops Universal Antibody Lock to Overcome the Trade Off Between Efficacy and Toxicity in Cancer Therapy
PrecisemAb Awarded the Title of “2025 Emerging High-Potential Startup”
PrecisemAb Biotech has been honored by the Small and Medium Enterprise Administration, Ministry of Economic Affairs,…
PrecisemAb Impresses at US BIO and Bio Asia–Taiwan, Attracting Global Pharma Interest
PrecisemAb Biotech participated in the 2025 US BIO International Convention and Bio Asia–Taiwan, showcasing its Universal…
PrecisemAb Breaks Into the Final Six and Secures the Company First Prize at the 9th Startup Star Competition
PrecisemAb Biotech received the First Prize in the Company Category at the 9th Startup Star Pitch…
GlycoNex and PrecisemAb Co-Develop an Innovative Pro-Antibody Demonstrating High Tumor Selectivity and Safety; Research Published in an International Journal
PrecisemAb Biotech Co., Ltd. extends its sincere congratulations to the team at GlycoNex Inc.! We are…
PrecisemAb Biotech Unveils an Innovative Antibody Lock Mechanism to Overcome Anti-Idiotypic Antibody Interference in Long-Term Antibody Therapies
We are excited to announce our second publication of the year.The study titled “Spatial-hindrance-based pro-Adalimumab prevents…
PrecisemAb Publishes New Research on Tumor-Selective Activation Antibodies in the International Journal of Biological Macromolecules
We are pleased to share that our latest research article,“Development of a tumor-region-selective activation monoclonal antibody…